Has Earl Hope, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,247 in general payments to Earl Hope, MD across 209 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Earl Hope, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Earl Hope, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Earl Hope, MD

Interventional Cardiology · West Reading, PANPI 1043299480

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,645 of the $5,247 with a category attached, or 88.5%. It is spread thinly across 37 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$5,247in general payments, 2019–2025

Across 209 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$1K
E.r. Squibb & Sons, L.L.C.$685
Johnson & Johnson$638
AstraZeneca$401
Boston Scientific$372
Bayer$325
plus $2K from 31 others

$72,806in research payments, 2019–2025

Across 37 payments — averaging $1967.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

CSL Behring$73K

What the payments were for

Consulting fees$3256%
Speaking & faculty fees$1002%
Food & beverage$4,64589%
Education$1783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	62	$1,169
E.r. Squibb & Sons, L.L.C.	37	$685
Johnson & Johnson	28	$638
AstraZeneca	15	$401
Boston Scientific	4	$372
Bayer	2	$325
Impulse Dynamics (USA) Inc.	3	$198
Abiomed	2	$170
Abbott	1	$150
Scpharmaceuticals Inc.	3	$148
United Therapeutics Corporation	4	$146
Novartis	8	$129
Sanofi-aventis U.S. LLC	6	$83
Atricure, Inc.	1	$59
Amgen	4	$57
Siemens Medical Solutions USA, Inc.	3	$42
Medtronic	1	$40
Actelion Pharmaceuticals US, Inc.	2	$35
Cardiovascular Systems Inc.	2	$33
Mannkind Corporation	1	$28
Lundbeck LLC	2	$26
Boehringer Ingelheim	2	$25
Akcea Therapeutics, Inc.	1	$23
Philips North America LLC	1	$23
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$23
Livanova USA, Inc.	1	$22
Edwards Lifesciences	1	$21
Heartflow, Inc.	1	$21
GE HealthCare	1	$21
Lexicon Pharmaceuticals, Inc.	1	$20
Vifor Pharma, Inc.	1	$19
Medicomp Inc	1	$19
Biotronik Inc.	1	$18
Terumo Medical Corporation	1	$15
Preventice Services, LLC	1	$15
Lilly USA, LLC	1	$15
Portola Pharmaceuticals, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Adempas$325
OPTIMIZER$241
Impella$150
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
GENERAL PAIN MANAGEMENT$146
FUROSCIX$110

How this compares

$5,247 in reported general payments places this provider in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$129,648

Medicare patients

3,066

Services billed

4,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	141	$139,273
OpsumitMacitentan	11	$133,726
CamzyosMavacamten	12	$102,938
Repatha SureclickEvolocumab	70	$53,430
EntrestoSacubitril/Valsartan	23	$39,770
JardianceEmpagliflozin	20	$17,900
Atorvastatin Calcium	192	$2,800
Metoprolol Succinate	159	$2,365
Dabigatran EtexilateDabigatran Etexilate Mesylate	12	$2,086
ClopidogrelClopidogrel Bisulfate	148	$1,612
Rosuvastatin Calcium	67	$1,548
Losartan Potassium	106	$1,286
Metoprolol Tartrate	123	$1,109
Ezetimibe	38	$983
Isosorbide Mononitrate ErIsosorbide Mononitrate	54	$568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$1,169	$139,273141 claims
Actelion Pharmaceuticals US, Inc.Opsumit	$35	$133,72611 claims
E.r. Squibb & Sons, L.L.C.Camzyos	$685	$102,93812 claims
NovartisEntresto	$129	$39,77023 claims
Boehringer IngelheimJardiance	$25	$17,90020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.